跳至主要内容
临床试验/NCT07572175
NCT07572175尚未招募2 期

SPARTACUS Trial (Sotagliflozin as Prevention of Antracycline-Related Toxicity in Adipose, Cardiac and mUskuloSkeletal Tissues)

Icahn School of Medicine at Mount Sinai1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2026年7月1日最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
60
试验地点
1

研究概览

简要总结

This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients ≥ 18 years
  • Newly diagnosed lymphoma
  • Scheduled to receive high-dose anthracycline (cumulative dose ≥ 300 mg/m2)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-3

排除标准

  • Prior anthracycline treatment
  • Previous malignancy requiring any chemotherapy or radiotherapy
  • Previous treatment with SGLT2i (eg due to T2DM) or SGLT1/2i
  • Previous heart failure (HF patients should already be on SGLT2i as per guidelines)
  • LVEF<40% (even in the absence of HF):
  • Pregnancy or breastfeeding
  • Standard contraindication to MRI (claustrophobia, non-MRI compatible devices)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Carlos Santos-Gallego

Cardiologist, Assistant Professor of Cardiology

Icahn School of Medicine at Mount Sinai

研究点 (1)

Loading locations...

相似试验